Searching News Database: Nexavar
HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
HSMN NewsFeed - 20 May 2014
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 6 Jan 2014
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
HSMN NewsFeed - 22 Jan 2013
Tau Therapeutics Hires Chief Medical Officer and VP of Operations and Strategy
Tau Therapeutics Hires Chief Medical Officer and VP of Operations and Strategy
HSMN NewsFeed - 13 Dec 2012
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 18 Oct 2012
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
HSMN NewsFeed - 31 Aug 2011
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
HSMN NewsFeed - 19 Jan 2011
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 12 Feb 2008
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
HSMN NewsFeed - 2 Aug 2007
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 28 Nov 2006
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Additional items found! 12
Members Archive contains
12 additional stories matching:
Nexavar
(Password required)
Nexavar
(Password required)